Trinity Biotech

Trinity Biotech Financing Cash Flow

The Net Financing Cash Flow of Trinity Biotech (TRIB) as of Oct 16, 2026 is 12.05 M USD. In the previous year, Net Financing Cash Flow was 28.81 M USD — a change of -58.17% (lower).

Financing Cash Flow

12.05 MUSD

YoY

-58.17%

Last updated:

Net Financing Cash Flow of Trinity Biotech is 2025 12.05 M USD. Net Financing Cash Flow of Trinity Biotech was 2024 28.81 M USD. It decreases by -58.17% lower compared to the previous year.

The Trinity Biotech Financing Cash Flow history

  • 3 Years

  • 10 Years

  • 25 Years

  • Max

Financing Cash Flow
Date
Financing Cash Flow
Jan 1, 2018
-16.98 M USD
Jan 1, 2019
-4.00 M USD
Jan 1, 2020
-2.72 M USD
Jan 1, 2021
-6.02 M USD
Jan 1, 2022
-12.32 M USD
Jan 1, 2023
-16.04 M USD
Jan 1, 2024
28.81 M USD
Jan 1, 2025
12.05 M USD
The Trinity Biotech Financing Cash Flow history
YEARFinancing Cash FlowYoY
12.05 MUSD-58.17%
28.81 MUSD-279.59%
-16.04 MUSD+30.19%
-12.32 MUSD+104.72%
-6.02 MUSD+121.61%
-2.72 MUSD-32.03%
-4.00 MUSD-76.47%
-16.98 MUSD+11.37%
-15.25 MUSD-6.69%
-16.34 MUSD-115.83%
103.23 MUSD-2,152.33%
-5.03 MUSD—

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Trinity Biotech Stock analysis

What does Trinity Biotech do? Trinity Biotech PLC is a healthcare company based in Bray, Ireland, with a focus on developing, manufacturing, and marketing medical diagnostic products. The company serves the clinical laboratory and point-of-care segments of the diagnostic market. Trinity Biotech employs 579 full-time staff and has been publicly traded since its IPO on October 21, 1992. Its products are designed to detect autoimmune, infectious, sexually transmitted diseases, diabetes, and disorders of the liver and intestine. The company operates through two geographic segments: the Americas and Rest of World. Product categories include point-of-care diagnostics, emergency medicine diagnostics, clinical laboratory reagents, and blood bank screening. The company's point-of-care brands are Uni-Gold and Recombigen, while its emergency medicine diagnostics cover acute care testing, STAT labs, pre/post-operative units, physician office labs, and central laboratories. Trinity Biotech supplies the clinical laboratory market with reagent products and other solutions through its clinical chemistry business. The blood bank screening division manufactures products to screen donated blood for transfusion-transmissible infections. The company's website is www.trinitybiotech.com. Trinity Biotech PLC is listed on the stock market under the ticker TRIB and ISIN US8964385046. The company's headquarters are located in Bray, Wicklow, Ireland. Trinity Biotech is one of the most popular companies on Eulerpool.

Frequently Asked Questions about Trinity Biotech stock

Net Financing Cash Flow of Trinity Biotech is 12.05 M USD in 2025.

Net Financing Cash Flow of Trinity Biotech changed from 28.81 M USD to 12.05 M USD, representing a -58.17% change. The value is lower than the previous year.

On Eulerpool you can find the complete historical development of Net Financing Cash Flow Trinity Biotech since 2006 – with annual values, charts, and detailed analysis.

Financing cash flow measures cash flows from debt issuance/repayment, equity transactions, and dividend payments.

Net Financing Cash Flow's USD is a key factor for investors. Changes in this metric can signal improving or deteriorating fundamentals, directly impacting the stock price. On Eulerpool, you can track Net Financing Cash Flow's Trinity Biotech historically and in real time.

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Cash Flow — Trinity Biotech

All Key Metrics — Trinity Biotech